🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 61 of 857 · Phase 3 first, then by program name

  1. Elenestinib

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis

    phase 3 small molecule active

    1 trial

  2. Eligard 22,5 mg poeder en oplosmiddel voor oplossing voor injectie

    Disc Medicine

    Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

    phase 3 small molecule active

    1 trial

  3. Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat, Eliglustat, Cerezyme 400 Units Powder for concentrate for solution for infusion, Eliglustat

    Genzyme Europe B.V.

    Gaucher's disease type I; Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  4. Eliquis 5 mg film-coated tablets, ACETYLSALICYLIC ACID

    Pari Pharma GmbH

    Aortic bioprothesis implanted patient for valvular heart disease

    phase 3 small molecule active

    1 trial

  5. Eloralintide

    Eli Lilly and Company

    Obesity

    phase 3 small molecule active

    1 trial

  6. Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  7. Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  8. Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  9. Elritercept

    Takeda

    Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  10. Eltrombopag

    GlaxoSmithKline

    Non-alcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial

  11. Eltrombopag 25 MG Oral Tablet

    The First People's Hospital of Lianyungang

    Stem Cell Transplant Complications

    phase 3 small molecule completed

    1 trial

  12. Emicizumab

    Takeda

    Hemophilia A

    phase 3 small molecule active

    1 trial

  13. Emixustat

    BRIGHT MINDS BIOSCIENCES INC.

    Stargardt Disease

    phase 3 small molecule completed

    1 trial

  14. Empagliflozin

    Boehringer Ingelheim

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  15. Empagliflozin

    Boehringer Ingelheim

    Heart Failure

    phase 3 small molecule completed

    1 trial

  16. Empagliflozin

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  17. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial

  18. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial

  19. Empagliflozin 10 mg

    United Therapeutics Europe Ltd

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial

  20. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  21. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. Empowered Relief On-Demand

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 3 other completed

    1 trial

  23. Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe

    Mabxience Research SL

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  24. Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection

    Janssen-Cilag International N.V.

    Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources